# John Beadle

> John Beadle is a biotechnology entrepreneur and board director based in the Greater Oxford Area. He co-founded PowderMed, acquired by Pfizer in 2006, and was the founding CEO of PsiOxus, now Akamis Bio. His subsequent roles include non-executive chair of Vitarka and board membership at Nykode, alongside other biotechnology directorships.

- **Role:** Non-Executive Chair at Vitarka Therapeutics; Board Member and R&D Committee Chair at Nykode Therapeutics
- **Organizations:** Akamis Bio (formerly PsiOxus Therapeutics), PowderMed, Pfizer, PowderJect Pharmaceuticals, GSK, Imperial Innovations, Myotec Therapeutics, Hybrid BioSystems, Vitarka Therapeutics, Nykode Therapeutics, Pneumagen, CamGene Therapeutics, Icosphere Biosciences, Scarlet Therapeutics, NorthLinks Bio, InnDura Therapeutics, Concordas
- **Education:** Bachelor of Medicine (MBBCh), University of the Witwatersrand, MBA, with distinction, London Business School, DA, Anaesthesia, South African College of Medicine
- **Known for:** Co-founded PowderMed and helped raise £20 million in 2004 before its 2006 acquisition by Pfizer., Led Myotec and Hybrid BioSystems through the combination that formed PsiOxus in 2010., Led PsiOxus during its 2016 BMS partnering agreements.

## Career timeline

- **1993-2001** — Held successive GSK roles, including business process improvement and vice president of global medical operations.
- **2001-2003** — Vice President, Medical and Product Development, PowderJect Pharmaceuticals.
- **2003-2004** — Co-founder, Commercial Director and Company Secretary, Concordas.
- **2004-2006** — Co-founder and Chief Medical Officer of PowderMed; helped raise £20 million in 2004.
- **2006** — Pfizer acquired PowderMed; acquisition completed in December.
- **2006-2007** — Site Head at Pfizer.
- **2007-2008** — Entrepreneur in Residence at Imperial Innovations.
- **2008** — Became CEO of Myotec in late 2008 and also led Hybrid BioSystems.
- **2009-2021** — Founding Chief Executive Officer of PsiOxus, according to Nykode’s published career chronology.
- **2010** — Myotec and Hybrid merged to form PsiOxus; £3.6 million additional financing accompanied the merger.
- **2012** — PsiOxus opened purpose-designed laboratory facilities at Milton Park.
- **2016** — PsiOxus signed a BMS worldwide licence agreement with $50 million upfront and up to $886 million in conditional milestones.
- **2021-2022** — Non-Executive Director of PsiOxus.
- **2021-2024** — Non-Executive Chairman of InnDura Therapeutics.
- **2022** — Appointed Non-Executive Director of Pneumagen.
- **2024** — Appointed Chairman of Vitarka Therapeutics in November.
- **2025** — Became Non-Executive Director of CamGene Therapeutics and Icosphere Biosciences.
- **2026** — Joined Nykode’s Board of Directors in January; named chair of its R&D Committee.

## Achievements

- Co-founded PowderMed and helped raise £20 million in 2004 before its 2006 acquisition by Pfizer.
- Led Myotec and Hybrid BioSystems through the combination that formed PsiOxus in 2010.
- Led PsiOxus during its 2016 BMS partnering agreements.
- Earned an MBA with distinction from London Business School.

## Latest updates

- **2026-01** — Joined Nykode’s board; its 2025 annual report, published in 2026, also identifies him as R&D Committee Chair.
- **2025-12** — Nykode’s December 2025 nomination document records CamGene and Icosphere non-executive directorships beginning in 2025.
- **2024-11** — Vitarka announced his appointment as Chairman.

## Links

- LinkedIn: https://uk.linkedin.com/in/john-beadle-18052b
- Bluesky: https://bsky.app/profile/johnb1.bsky.social

---

Profile page: https://yespress.io/john-beadle
Published by YesPress — https://yespress.io
Last updated: 2026-10-11